olivLaw · US equity research
Molina Healthcare, Inc. MOH
Hospital & Medical Service Plans · SIC 6324 · Vertical: Hospital & Medical Service Plans (SIC 6324)
Molina Healthcare is a managed healthcare company focused entirely on government-sponsored programs: Medicaid, Medicare and state insurance marketplaces. The company is going through a difficult stretch, with medical costs rising faster than the rates it receives and margins sharply compressed; in fiscal 2025 the consolidated MCR reached 91.7% while total revenue reached 45.4 billion USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Molina Healthcare, Inc. (MOH) stock was 226.42 USD (+8.93% on the day), with market capitalisation 11.8 bn USD, beta 0.07, 52-week range 122.65–242.88 USD. Latest reported quarter (Q3 2026): revenue of 11.1 bn USD (−3.4% YoY), net income of 38.0 m USD (−51.9% YoY), diluted EPS 0.73 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 67.1
- strong (55–70)
- Bollinger (20, 2)
- 192.34 – 223.16
- above the upper band · %B 1.11 · band width 14.8%
- SMA 50 / 200
- 201.47 / 185.23
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 3.11 / 2.23
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +16.7% | −1.1% | +17.8 pp | — |
| 3 months | +16.0% | −0.5% | +16.5 pp | — |
| 6 months | +14.7% | +4.4% | +10.3 pp | — |
| Year to date | +30.5% | +12.3% | +18.2 pp | — |
| 1 year | +49.3% | +13.5% | +35.7 pp | +28.4% |
| 3 years | −32.9% | +76.4% | −109.3 pp | +8.5% |
| 5 years | −25.6% | +63.7% | −89.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.5 bn | 11.1 bn | 11.4 bn | 11.5 bn | 11.4 bn | 10.8 bn | 10.9 bn | 11.1 bn |
| Cost of revenue | 9.0 bn | 9.5 bn | 9.8 bn | 10.0 bn | 10.1 bn | 9.3 bn | 9.4 bn | 9.7 bn |
| Operating income | 380.0 m | 433.0 m | 373.0 m | 137.0 m | -162.0 m | 83.0 m | 145.0 m | 106.0 m |
| Depreciation & amortisation | 48.0 m | 48.0 m | 58.0 m | 45.0 m | 44.0 m | 39.0 m | 40.0 m | 38.0 m |
| Interest expense | 34.0 m | 43.0 m | 48.0 m | 49.0 m | 52.0 m | 54.0 m | 54.0 m | 53.0 m |
| Pre-tax income | 346.0 m | 390.0 m | 325.0 m | 88.0 m | -214.0 m | 29.0 m | 91.0 m | 53.0 m |
| Income tax | 95.0 m | 92.0 m | 70.0 m | 9.0 m | -54.0 m | 15.0 m | 31.0 m | 15.0 m |
| Net income | 251.0 m | 298.0 m | 255.0 m | 79.0 m | -160.0 m | 14.0 m | 60.0 m | 38.0 m |
| Diluted EPS | 4.44 ≈ | 5.45 | 4.75 | 1.51 | -3.15 ≈ | 0.27 | 1.19 | 0.73 |
| Operating cash flow | -224.0 m | 190.0 m | -302.0 m ≈ | -125.0 m ≈ | -298.0 m | 1.1 bn | -294.0 m ≈ | -159.0 m ≈ |
| Capex | 11.0 m | 22.0 m | 42.0 m ≈ | 38.0 m ≈ | -1.0 m | 27.0 m | 30.0 m ≈ | 37.0 m ≈ |
| Share repurchases | 500.0 m | 500.0 m | 0 ≈ | 500.0 m ≈ | 0 | 0 | 0 ≈ | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.9 bn | 16.8 bn | 19.4 bn | 27.8 bn | 32.0 bn | 34.1 bn | 40.7 bn | 45.4 bn |
| Revenue YoY | −5.0% | −10.9% | +15.4% | +43.0% | +15.1% | +6.6% | +19.3% | +11.7% |
| Net income | 707.0 m | 737.0 m | 673.0 m | 659.0 m | 792.0 m | 1.1 bn | 1.2 bn | 472.0 m |
| Net income YoY | unavailable | +4.2% | −8.7% | −2.1% | +20.2% | +37.8% | +8.1% | −60.0% |
| Diluted EPS | 10.61 | 11.47 | 11.23 | 11.25 | 13.55 | 18.77 | 20.42 | 8.92 |
| Diluted EPS YoY | unavailable | +8.1% | −2.1% | +0.2% | +20.4% | +38.5% | +8.8% | −56.3% |
| net % | 3.7% | 4.4% | 3.5% | 2.4% | 2.5% | 3.2% | 2.9% | 1.0% |
| Free cash flow | -344.0 m | 377.0 m | 1.8 bn | 2.0 bn | 682.0 m | 1.6 bn | 544.0 m | -636.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 4.2 bn USD
- Financial debt
- 3.8 bn USD
- Net debt
- -482.0 m USD
- Equity
- 4.1 bn USD
- Total assets
- 15.6 bn USD
- Debt / equity
- 0.93x
- Current ratio
- 1.69x
- ROE
- 11.0%
- ROA
- 3.0%
- FCF margin
- -1.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Pre-tax income | 961.0 m | 875.0 m | 1.1 bn | 1.5 bn | 1.6 bn | 589.0 m | SEC (XBRL)· 10 Feb 2026verified |
| Net income | 673.0 m | 659.0 m | 792.0 m | 1.1 bn | 1.2 bn | 472.0 m | SEC (XBRL)· 10 Feb 2026verified |
| Diluted EPS | 11.23 | 11.25 | 13.55 | 18.77 | 20.42 | 8.92 | SEC (XBRL)· 10 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 4.2 bn | 4.4 bn | 4.0 bn | 4.8 bn | 4.7 bn | 4.2 bn | SEC (XBRL)· 10 Feb 2026verified |
| Total assets | 9.5 bn | 12.2 bn | 12.3 bn | 14.9 bn | 15.6 bn | 15.6 bn | SEC (XBRL)· 10 Feb 2026verified |
| Short-term debt | 0 | — | — | — | — | — | SEC (XBRL)· 16 Feb 2021verified |
| Long-term debt | 2.1 bn | 2.2 bn | 2.2 bn | 2.2 bn | 2.9 bn | 3.8 bn | SEC (XBRL)· 10 Feb 2026verified |
| Total liabilities | 7.4 bn | 9.6 bn | 9.4 bn | 10.7 bn | 11.1 bn | 11.5 bn | SEC (XBRL)· 10 Feb 2026verified |
| Equity | 2.1 bn | 2.6 bn † | 3.0 bn † | 4.2 bn † | 4.5 bn † | 4.1 bn † | SEC (XBRL)· 10 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Share repurchases | 606.0 m | 128.0 m | 400.0 m | 0 | 1.0 bn | 1.0 bn | SEC (XBRL)· 10 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Market and valuation
Insurance
32 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 58.0% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 11.8 bn USD
Key indicators
Coverage and freshness
Score by group
58% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 60.75 – 263.97 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- Residual income60.75 – 63.52 (Mid 62.11)
- Justified P/Bunavailable · insufficient data
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
- Peers: P/Eunavailable · the base of the ratio is not positive
- Peers: P/B154.82 – 263.97 (Mid 190.91)6 companies used · median multiple 2.4x · quartiles 1.9x – 3.3xCI, CNC, ELV, HUM, TRUP, UNH
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 58.0% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROE · Quality | -1.2% | 13 (vs peers) | 31% |
| Loss ratio · Quality | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | -13.0% | 0 (on a fixed band) | 17% |
| Revenue CAGR 3Y · Growth | 12.4% | 100 (on a fixed band) | 14% |
| ROA · Balance sheet | -0.3% | 0 (on a fixed band) | 14% |
| P/B · Valuation | 2.8x | 43 (vs peers) | 24% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| Dividend yield · Returns | unavailable | unavailable | — |
| Payout ratio (EPS) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 1/1 factors with a value
- Growth44/100 · 2/2 factors with a value
- Quality· partial13/100 · 1/2 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial43/100 · 1/2 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
MOLINA HEALTHCARE, INC. (MOH). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: YoY growth 11.7%; net margin -0.1%; ROE -1.2%.
The estimated value range is 107.78–163.75 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 126.51 USD, the price of 226.42 USD leaves a potential of -44.1% (value / price − 1) and a margin of safety of -79.0% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 58.0% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 12.4%
What contradicts it
- ROE: -1.2%
- EPS CAGR 3Y: -13.0%
- ROA: -0.3%
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Loss ratio, P/E (TTM), Dividend yield, Payout ratio (EPS).
Versus the vertical median
Hospital & Medical Service Plans (SIC 6324) · same industry (4-digit SIC) · compared with 9 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| UNHUnitedHealth Group Incorporated | 366.8 bn | 23.4 | 15.4% | 3.5% | +11.8% | +24% / −26% |
| ELVElevance Health, Inc. | 93.8 bn | 18.5 | 11.6% | 2.5% | +12.5% | +28% / −9% |
| CIThe Cigna Group | 80.7 bn | 13.2 | 15.0% | 2.2% | +11.2% | +10% / +16% |
| HUMHumana Inc | 50.1 bn | 44.5 | 6.2% | 0.8% | +10.1% | +70% / −14% |
| CNCCentene Corporation | 37.6 bn | 26.0 | 6.8% | 0.7% | +19.4% | +93% / +3% |
| MOHMolina Healthcare, Inc. | 11.8 bn | — | -1.2% | -0.1% | +11.7% | +49% / −33% |
| ALHCAlignment Healthcare, Inc. | 1.7 bn | 71.3 | 13.2% | 0.6% | +46.1% | −58% / +9% |
| TRUPTrupanion, Inc. | 1.5 bn | 74.8 | — | — | +11.9% | −5% / +31% |
| OSCROscar Health, Inc. | — | 25.2 | 34.3% | 3.6% | +27.5% | +96% / +314% |
| CLOVClover Health Investments, Corp. | — | — | -5.1% | -0.7% | +40.3% | +88% / +409% |
1- and 3-year price returns: for MOH from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 21 Oct 2026; since then the company filed 10-Q (22 Oct 2026).
In brief
Molina Healthcare is a managed healthcare company focused entirely on government-sponsored programs: Medicaid, Medicare and state insurance marketplaces. The company is going through a difficult stretch, with medical costs rising faster than the rates it receives and margins sharply compressed; in fiscal 2025 the consolidated MCR reached 91.7% while total revenue reached 45.4 billion USD 1.
SWOT
Strengths
- The company has a solid track record of winning re-procurement bids, with a high reported success rate 1.
- The pure-play government business model offers a focused and predictable customer base 1.
- The balance sheet is sound, with parent-company liquidity and the capacity to return capital to shareholders 2.
Weaknesses
- Margins are very thin, and small deviations from medical cost estimates can have disproportionate effects on profit 1.
- Profitability depends on predicting medical costs accurately, which has proven difficult in recent years 1.
- State contracts rely on rates that have lagged costs, creating an imbalance between rates and trend 1.
Opportunities
- Acquisitions of smaller regional plans could expand the member base, as many such plans are exploring strategic options 1.
- The 2027 rate updates and a stabilizing medical cost trend could support a recovery in Medicaid margins 2.
- Integrating dual-eligible populations could open demand for more coordinated services 1.
Risks
- State rates could remain below medical costshigh
If rates paid by states grow more slowly than medical costs, margins could be compressed or eliminated, and earnings could be affected 1.
- Dependence on a few stateshigh
A small number of Medicaid contracts in states such as California, New York, Texas and Washington generate a large share of revenue, so a loss could have material effects 1.
- Volatility of the Marketplace segmentmedium
Marketplace enrollment is sensitive to prices and subsidies, and annual changes can be difficult to price actuarially 1.
- Reserve development and retroactive adjustmentsmedium
Retroactive adjustments or recoupments by states can create uncertainty over recognized revenue and affect quarterly results 1.
- Cybersecurity and third-party vendor risksmedium
The company relies on third parties for services and sensitive data, and a security incident could generate costs, sanctions and reputational damage 1.
Investment thesis
What would need to be true (bull case)
- If the stabilization of medical costs is confirmed and the 2027 rate updates translate into better margins, earnings could return to an upward path 2.
- The company has a track record of winning bids and an acquisition strategy that could expand its member base in an accretive way 1.
- Investments in artificial intelligence and cost management could produce efficiencies that support margins over the medium term 1.
What would break the thesis
- If pressure from medical costs persists at elevated levels, the MCR could remain above the long-term target, weighing on profit 1.
- Declining Medicaid and Marketplace enrollment, driven by redeterminations and the expiration of subsidies, could reduce premium revenue more than anticipated 1.
- The very thin operating margin leaves little room for error, so one lost rebid or one wrong estimate could have a material impact 1.
What to watch
- Medicaid MCR trajectory and confirmation that the medical cost trend has stabilizedQ4 2026
- Impact of the Florida Medicaid contract on margins, given the expected 1.50 USD per share lossQ4 2026
- Full year 2027 guidance and the effect of rate updates on the MCR2027
- Evolution of Marketplace enrollment after subsidy expiration, as reported in the next annual reportnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 21 Oct 2026; since then the company filed 10-Q (22 Oct 2026).
The business
Molina Healthcare, Inc. is a FORTUNE 500 company that provides managed healthcare services through Medicaid and Medicare programs and state insurance marketplaces, serving about 5.5 million members across 21 states as of December 31, 2025 1. The company describes itself as a pure-play government-sponsored healthcare business, with revenue coming mainly from premiums paid monthly per member by states and the federal government 1.
The business model means Molina bears medical cost risk: premiums are fixed by contract, while the company pays for the services delivered to members 1. Margins are therefore very thin, and gaps between actual costs and rates pass directly into profit or loss 1. The long-term strategy targets organic growth and accretive acquisitions, with a premium revenue growth target of 11% to 13% 1.
In 2025 the company closed the ConnectiCare acquisition, at a purchase price of 350 million USD, and won several Medicaid and Medicare procurements, including in Idaho, Michigan, Florida and Illinois 1. For 2026 management reaffirmed premium and adjusted earnings guidance, while the third quarter of 2026 showed continued margin pressure 2.
Segments
Medicaid
Medicaid is the largest segment, representing 75% of consolidated premium revenue in fiscal 2025 1. Segment premium revenue was 32.2 billion USD in 2025, and the MCR rose to 91.8%, above 2024 levels 1. Four largest regional health plans, in California, New York, Texas and Washington, concentrated a large share of this revenue 1.
Medicare
The Medicare segment, with premium revenue of 6.2 billion USD in 2025, grew mainly thanks to members from ConnectiCare, but its MCR reached 92.4% due to high utilization in the high-acuity population 1. The company exited MAPD products in thirteen states to focus on the dual-eligible population 1.
Market context
The market Molina operates in is dominated by government programs, where states award contracts through periodic bids, usually for three to five years 1. Competition for contracts is intense, and losing a contract at rebid can significantly reduce revenue 1.
State rates are usually updated once a year, and cost growth has recently outpaced these adjustments, compressing margins across the industry 1. The company notes that the cost trend appears to be plateauing at elevated levels, and recent 2027 rate updates could signal a turn in Medicaid margins 2.
Trends
- Rising medical costsheadwind
Medical costs and utilization grew faster than the rates received from states, compressing the MCR across all segments in 2025 1. If the trend stabilizes, as management suggested in the third quarter of 2026, margin pressure could ease 2.
- Lower Medicaid enrollmentmixed
Medicaid enrollment has declined due to eligibility redeterminations, and management expects a flat population in 2026 as new contracts such as Florida Kids offset contraction 1. Lower membership may limit revenue growth, but the remaining population tends to have higher medical needs 1.
- Expiration of Marketplace subsidiesheadwind
The expiration of certain premium tax credits at the end of 2025 could reduce enrollment and produce an adverse shift in the risk pool 1. This pressures volume in the Marketplace segment, which depends on prices and subsidies 1.
- Integration of dual-eligible membersmixed
Integrating Medicaid and Medicare programs for dual-eligible members in many states creates both an opportunity and a threat, offering access to high-need populations but also operational risks 1. The company exited MAPD products to focus on this population 1.
- Artificial intelligence and efficiencytailwind
The company is making substantial investments in artificial intelligence tools to improve effectiveness and control medical and administrative costs 1. The effect on margins could become visible if these investments reduce unit costs over the medium term 1.
Competitive position
Molina competes with other government-sponsored health plan providers for state contracts, through bids where price, performance and operational experience matter 1. The supplied sources do not explicitly name competitors, so the list below reflects only the categories implied in the documents.
Competition is even stronger in the Marketplace and Medicare markets, because members choose plans on price and switch providers quickly 1. A provider with lower costs or a better risk profile could win contracts at the company's expense 1.
- Other Medicaid managed care plan providers
Companies bidding for the same state Medicaid contracts, though the sources do not name them explicitly.
- Medicare Advantage plan providers
Providers offering MAPD plans that compete for the Medicare population in the same states.
- Marketplace plan providers
Companies selling plans on state insurance marketplaces that are sensitive to the same premium subsidies.
- Smaller or less diversified health plans
Regional providers that, according to management, could consider strategic options in the current challenging operating environment.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Doi coechipieri, Dybala și Molina, nu sunt lăsați să participe la meciul de retragere al lui Messi din naționala ArgentineiG4Media · 30 Sept 2026 · RO
- Anthony Molina turns in strong outing as SF Giants lose to TwinsSurge — GDELT DOC · 23 Sept 2026 · RO
- Molina Healthcare (MOH) Jumped 70.7% in Q2: Why the Stock Rally Was Enough to SellYahoo Finance — News · 21 Sept 2026 · EN
- FIFA a anunțat sancțiunile pentru jucătorii echipei naționale a Argentinei care i-au lovit pe cei ai Spaniei, imediat după finala Cupei Mondiale. Leandro Paredes și Nahuel Molina au fost suspendați pentru zece, respectiv pentru șapte meciuri, și au fost amendați cu câte 90 de mii de dolari. Federația argentiniană va plăti și ea 221 de mii de dolari.Biziday.ro · 21 Aug 2026 · RO
- Fotbal: Argentinianul Nahuel Molina (Atletico Madrid) a semnat cu RomaAgerpres · 12 Aug 2026 · RO
- Avionul privat al legendei din baseball Yadier Molina s-a prăbușit și a explodat pe un aeroport din Republica DominicanăHotNews.ro · 08 Jun 2026 · RO
The latest news item in our archive is from 30 Sept 2026; the newest SEC filing is from 22 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report22 Oct 2026
- Current report21 Oct 2026Results of operations · Financial statements and exhibits
- Quarterly report23 Jul 2026
- Current report22 Jul 2026Results of operations · Financial statements and exhibits
- Current report10 Jun 2026Regulation FD disclosure · Financial statements and exhibits
- Current report11 May 2026Departure or appointment of officers · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Current report08 May 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report23 Apr 2026
- Current report22 Apr 2026Results of operations · Financial statements and exhibits
- Proxy statement23 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Molina Healthcare, Inc. · 10 Feb 2026
- [2] Form 8-K, results release (exhibit 99.1) · SEC / Molina Healthcare, Inc. · 21 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.